Clinical Trials Logo

Myeloid Leukemia clinical trials

View clinical trials related to Myeloid Leukemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01643603 Terminated - Multiple Myeloma Clinical Trials

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Start date: May 2012
Phase: Phase 1
Study type: Interventional

This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells. Researchers think that dasatinib may cause large granular lymphocyte expansion to happen in patients who have received a blood stem cell transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how to estimate how often large granular lymphocytic cellular expansion happens at the best dose of dasatinib.

NCT ID: NCT00967343 Terminated - Multiple Myeloma Clinical Trials

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Start date: August 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related, haploidentical donor enhances survival by improving the immune effect against infections while preventing graft-versus-host disease .

NCT ID: NCT00887926 Terminated - Myeloid Leukemia Clinical Trials

Study of IMC-EB10 in Participant With Leukemia

Start date: June 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.

NCT ID: NCT00543972 Terminated - Myeloid Leukemia Clinical Trials

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the maximum tolerated dose of AVE9633 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-leukemia activity, the global safety and the PK profile.

NCT ID: NCT00126893 Terminated - Myeloid Leukemia Clinical Trials

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Start date: October 2005
Phase: Phase 1
Study type: Interventional

This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.